Sana Biotechnology, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SANA research report →
Price Chart
About the company
Sana Biotechnology, Inc. is a biotechnology firm focused on creating treatments using engineered cells. The company develops advanced ex vivo and in vivo cell engineering platforms to address a range of conditions with significant unmet medical needs, including various cancers, diabetes, central nervous system disorders, cardiovascular diseases, and genetic illnesses.
- CEO
- Steven D. Harr
- IPO
- 2021
- Employees
- 142
- HQ
- Seattle, WA, US
Get TickerSpark's AI analysis on SANA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $1.04B
- P/E
- -4.92
- PEG
- -0.15
- P/S
- 0.00
- P/B
- 7.15
- EV/EBITDA
- -5.26
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -134.49%
- ROIC
- -64.54%
Latest fiscal year · YoY change
- Revenue
- $0
- Gross Profit
- $-12,750,000
- Op Income
- $-190,958,000
- Net Income
- $-244,166,000
- EPS
- $-0.96
- 52W High
- $6.55
- 52W Low
- $2.61
- 50D MA
- $3.40
- 200D MA
- $3.71
- Beta
- 2.10
- Avg Volume
- 3.29M
No earnings-call transcripts are available for SANA yet.
of shares held by institutions
206 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 37.43M | ▼ 769 |
| Flagship Pioneering Inc. | 25.00M | 0 |
| Ra Capital Management, L.P. | 18.75M | ▲ 18.75M |
| Blackrock, Inc. | 16.68M | ▲ 2.43M |
| State Street Corp | 11.20M | ▲ 665.05K |
| Vanguard Group Inc | 10.46M | ▲ 1.33M |
| Canada Pension Plan Investment Board | 10.22M | ▼ 3.50K |
| Vanguard Capital Management LLC | 8.38M | ▲ 940.70K |
| Bank Of America Corp | 5.75M | ▲ 2.80M |
| Geode Capital Management, LLC | 4.68M | ▲ 495.99K |
| Marex Group PLC | 3.99M | ▼ 10.00K |
| Marshall Wace, Llp | 2.93M | ▲ 2.27M |
Held by 187 ETFs
Biggest fund positions in SANA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 6, 26 | Bishop Hans Edgar | other | 6,297 |
| Jun 4, 26 | Yang Patrick Y | other | 90,000 |
| Jun 4, 26 | Rosiello Robert L. | other | 90,000 |
| Jun 4, 26 | Seitz Michelle | other | 90,000 |
| Jun 4, 26 | REICIN ALISE | other | 90,000 |
| Jun 4, 26 | Mulligan Richard | other | 90,000 |
| Jun 4, 26 | Bishop Hans Edgar | other | 90,000 |
| Jun 4, 26 | Bilenker Joshua H. | other | 90,000 |
| Jun 4, 26 | NELSEN ROBERT | other | 90,000 |
| Apr 6, 26 | Bishop Hans Edgar | other | 7,763 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SANA coverage
Recent articles, reports, and earnings notes.
No research on SANA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SANA report →Sana Biotechnology, Inc. (NASDAQ:SANA) Receives $9.50 Consensus PT from Brokerages
defenseworld.net · Jul 30
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com · Jul 29
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
zacks.com · Jul 20
Sana (SANA) Upgraded to Buy: Here's What You Should Know
zacks.com · Jul 15
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
globenewswire.com · Jul 13
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
globenewswire.com · Jul 1
Sana Biotechnology, Inc. (SANA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
seekingalpha.com · Jun 10
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
prnewswire.com · Jun 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.